Sugammadex Side Effects, Risks, and Drug Interactions

Sugammadex is widely considered safer than the older reversal agent it largely replaced, but it carries its own set of risks that anyone scheduled for surgery should know about. The most talked-about concerns include rare but real allergic reactions, cardiovascular events like slow heart rate and low blood pressure, and an interaction with hormonal contraceptives that can catch people off guard. Most side effects are mild and short-lived, yet the serious ones, though uncommon, have prompted enough case reports and post-marketing surveillance data to deserve a careful look.

How Sugammadex Works and Why That Matters for Side Effects

Sugammadex is a modified sugar molecule shaped like a hollow ring. After surgery, it wraps around the muscle-paralyzing drugs rocuronium or vecuronium, trapping them inside its cavity and pulling them away from the nerve-muscle junction. The complex is then filtered out by the kidneys and excreted in urine. This encapsulation process is driven by a combination of forces between the two molecules, and the fit is remarkably tight.¹ That tight binding is what makes sugammadex fast and predictable, but it’s also what creates some of its unique interactions: the ring doesn’t only grab paralytic drugs. It can also encapsulate other steroid-shaped molecules floating around in your blood, and that has consequences.

Allergic and Hypersensitivity Reactions

The risk that gets the most attention in the anesthesiology literature is anaphylaxis, a severe whole-body allergic reaction. The good news is that this is genuinely rare. Post-marketing surveillance published in 2016 suggested roughly 1 case per 42,000 exposures worldwide, and a large Australian study across six allergy clinics estimated an incidence of about 0.004%, or roughly 1 in 25,000 administrations.² These numbers are low enough that most anesthesiologists will go years without seeing a case.

Japan is an interesting outlier. Sugammadex has been used there as a first-line reversal agent since 2010, and reported incidences have been considerably higher, ranging from about 1 in 2,500 to 1 in 5,000 in different studies. Why Japan sees more cases isn’t entirely settled, though genetic factors and reporting practices may play a role. Overall, outside of Japan, the signal has not risen to the level where regulators consider sugammadex hypersensitivity a widespread clinical problem.³

When allergic reactions do occur, the evidence points toward an IgE-mediated mechanism, the same type of immune response behind classic drug allergies. In the Australian cohort, blood tests for a marker called tryptase were positive in all life-threatening cases and in about 70% of non-life-threatening ones, and skin testing confirmed sensitization.² Symptoms can range from a simple skin rash to full cardiovascular collapse. The timing is usually within minutes of the injection, which at least means it happens while you’re still in the operating room with a full team ready to respond.

Cardiovascular Events

Slow heart rate (bradycardia) and low blood pressure (hypotension) are among the more common serious concerns linked to sugammadex. Between 2014 and the end of 2020, the FDA’s adverse event reporting system logged 282 cases of major cardiac events following sugammadex, including 160 reports of bradycardia, 110 of cardiac arrest, 83 of hypotension, and 55 of low oxygen saturation.⁴ Those numbers sound alarming on their own, but they need context: millions of doses were administered during that period, and adverse event databases capture reports without proving that the drug caused the event. Patients waking up from surgery have plenty of other reasons for heart rate and blood pressure changes.

Still, individual case reports make a compelling argument that sugammadex can directly trigger cardiovascular collapse in some patients. One published case describes an 80-year-old man with no history of heart disease who developed severe hypotension, asystole (a flatline), and cardiac arrest immediately after receiving sugammadex. The clinical team investigated other potential causes and concluded sugammadex was the most likely culprit.⁵ Proposed mechanisms include a sudden drop in the circulating levels of steroidal substances (not just the paralytic drug) and possible vagal nerve stimulation, though the exact pathway remains debated.

Respiratory Complications

Bronchospasm, a sudden tightening of the airways, has been reported after sugammadex injection.⁶ A post-marketing analysis of the FDA’s database found a statistically significant signal linking sugammadex to both bronchospasm and coronary artery spasm, although the absolute number of coronary spasm reports was small.⁷ Bronchospasm during emergence from anesthesia can also be caused by the breathing tube itself, secretions in the airway, or the patient’s underlying lung disease, which makes it hard to pin every case on the drug. But the pharmacovigilance signal is strong enough that anesthesiologists treating patients with reactive airways should keep this risk in mind.

The Hormonal Contraceptive Problem

This is probably the most underappreciated interaction. Because sugammadex encapsulates steroid-shaped molecules, it can also grab progesterone circulating in your bloodstream. Lab studies suggest that progesterone levels could drop by roughly a third after exposure to sugammadex.⁸ That creates two distinct concerns. First, for someone relying on hormonal birth control (pills, patches, rings, or implants that contain progesterone or a synthetic version of it), a sudden dip in progesterone could reduce the contraceptive’s effectiveness for the remainder of that cycle. Second, for someone in very early pregnancy, a sharp progesterone drop could theoretically threaten the pregnancy, since progesterone is essential for maintaining the uterine lining in the first weeks.

The practical advice is straightforward: if you use hormonal contraception and receive sugammadex, most guidance recommends using a backup method (like condoms) for at least seven days afterward, just as you would if you had missed a dose of your pill. This is not a hypothetical lab curiosity. The interaction has been significant enough to earn a mention in the drug’s prescribing information, and it’s something your anesthesiology team should discuss with you before surgery if it applies.

Effects on Blood Clotting

Sugammadex appears to have a modest effect on clotting. A recent systematic review and meta-analysis found that it prolonged prothrombin time (one of the standard lab tests for how fast your blood clots) without significantly affecting another clotting measure called activated partial thromboplastin time.⁹ The quality of the evidence for the prothrombin time effect was graded as low, meaning it could shift as more studies accumulate.

What matters most is whether this lab change translates to actual bleeding in patients. The same meta-analysis looked at clinical bleeding outcomes and found mixed results: two studies showed comparable post-operative bleeding between sugammadex and control groups, while one smaller study found slightly more bleeding in the sugammadex group.⁹ For the vast majority of surgeries, this effect is unlikely to be clinically meaningful. But for patients already on blood thinners or undergoing procedures where even small amounts of extra bleeding are dangerous, it’s a factor your surgical team should weigh.

Kidney Function and Drug Clearance

The sugammadex-rocuronium complex is eliminated almost entirely by the kidneys, which creates an obvious problem for people whose kidneys don’t work well. In patients with severe kidney impairment, the clearance of sugammadex drops dramatically compared with healthy individuals.¹⁰ A separate trial in patients with severe renal impairment showed that while sugammadex still reversed the paralysis effectively, the drug-rocuronium complex remained detectable in the blood a full week later in some patients. The reversal itself worked, taking about 3 minutes compared with about 2 minutes in people with healthy kidneys, but the long-term exposure to the lingering complex raised enough safety questions that the investigators concluded the available data were insufficient to recommend routine use in this population.¹¹

The concern isn’t that the reversal fails. It’s that rocuronium, still trapped inside sugammadex, could potentially leak out if the complex sits in the blood long enough without being cleared, theoretically causing a return of paralysis. Whether this actually happens at clinically meaningful rates in renal patients remains unresolved.

How Sugammadex Compares to the Older Alternative

Before sugammadex, the standard approach to reversing neuromuscular blockade involved neostigmine combined with an anticholinergic drug. Neostigmine works by a completely different mechanism: rather than trapping the paralyzing drug, it blocks the enzyme that breaks down acetylcholine at the nerve-muscle junction, essentially boosting the body’s own signals to overpower the lingering paralytic. The tradeoff is that neostigmine also boosts acetylcholine everywhere else, which is why it requires a companion drug to control side effects like excessive salivation, slow heart rate, and gut cramping.

Head-to-head comparisons consistently favor sugammadex on safety. A meta-analysis of randomized controlled trials found that sugammadex was associated with roughly half the odds of adverse events overall, about a third the odds of respiratory problems, and about a quarter the odds of cardiovascular events compared with neostigmine.¹² A more recent comparative study reported that composite adverse events occurred in 12% of sugammadex patients versus 34% of neostigmine patients. Bradycardia requiring treatment was seen in 18% of the neostigmine group but only 2% of the sugammadex group, and low oxygen episodes were similarly far less common with sugammadex.¹³

Perhaps the most clinically important difference is residual paralysis, the scenario where a patient arrives in the recovery room still partially paralyzed. In that same comparative study, residual paralysis was present in 14% of neostigmine patients and zero sugammadex patients.¹³ Residual paralysis can weaken your breathing and your ability to protect your airway, so eliminating it is a genuine safety win.

Minor and Common Side Effects

At standard doses, the most frequently reported complaint in clinical trials is dysgeusia, a temporary bitter or metallic taste in the mouth. In a dose-ranging safety study that tested doses up to 96 mg per kilogram (far beyond what anyone receives clinically), sugammadex was well tolerated in nearly all subjects, with side effects being mild, brief, and more common at higher doses.¹⁴ Nausea, vomiting, headache, and injection-site discomfort round out the list of common minor effects, though separating these from the aftereffects of anesthesia itself is always tricky.

Interactions with Other Medications

Beyond the hormonal contraceptive issue, sugammadex’s potential to interact with other drugs has been studied in some detail. Because the molecule works by physically wrapping around steroid-shaped compounds, researchers tested whether it could pull other medications away from their targets. The binding affinity of sugammadex for rocuronium and vecuronium turns out to be extremely high, orders of magnitude stronger than for other tested compounds. Out of 21 commonly co-administered drugs analyzed across ten trials, only three (flucloxacillin, fusidic acid, and toremifene) had the right combination of binding strength and blood concentration to theoretically displace rocuronium from sugammadex. No actual return of paralysis was observed in any patient in those studies.¹⁵

The practical takeaway is that for the vast majority of drugs you might be taking, sugammadex won’t interfere. Toremifene (a breast cancer drug) is the one that occasionally shows up in clinical discussions as a theoretical concern, and fusidic acid (an antibiotic more common in Europe and Australia) is another. If you’re taking either, your anesthesiologist should know.

Getting the Dose Right and Recurrence of Paralysis

Sugammadex’s effectiveness depends heavily on matching the dose to the depth of the neuromuscular blockade. If the dose is too low relative to how much paralyzing drug is still active, the reversal can be incomplete or can wear off, allowing paralysis to partially return. This isn’t a flaw of the drug so much as a dosing challenge that requires objective monitoring of the nerve-muscle junction before and after administration. Conversely, giving a very large dose to “guarantee” full reversal can create its own problem: if the patient needs to be re-paralyzed urgently (say, for an emergency reoperation), the excess sugammadex will immediately scavenge any new dose of rocuronium, making it ineffective.¹⁶ In those situations, the surgical team may need to switch to a non-steroidal paralyzing agent like succinylcholine instead.

Children and Elderly Patients

An updated meta-analysis of randomized trials in children found that sugammadex was associated with less post-operative nausea and vomiting, less bradycardia, and fewer instances of dry mouth compared to control groups receiving other reversal agents.¹⁷ In infants under two years old with congenital heart disease, a recent study found that bradycardia occurred at a low and comparable rate whether sugammadex or another reversal method was used, and no cases of anaphylaxis were documented. Tracheal extubation was successful in over 90% of encounters in both groups.¹⁸

Elderly patients present a different calculus. They often have underlying heart disease, reduced kidney function, and less physiologic reserve to absorb hemodynamic swings. Yet the very properties that make sugammadex appealing in general, rapid reversal without the muscarinic side effects of neostigmine, may be especially valuable in this group. A case report of an 83-year-old man with ischemic heart disease, atrial fibrillation, and interstitial lung disease described a smooth reversal with sugammadex and minimal hemodynamic disturbance.¹⁹ Single cases don’t establish safety profiles, but they illustrate the clinical reasoning: in a frail patient whose heart might not tolerate the acetylcholine surge from neostigmine, sugammadex’s cleaner mechanism of action may offer a real advantage.

The Cost Question

Sugammadex is substantially more expensive per dose than neostigmine, and this price gap has been a major barrier to its adoption in many hospitals. One analysis at a Taiwanese university hospital found that the average drug cost of sugammadex was about $186 compared to roughly $23 for neostigmine, and the total reversal-related costs followed suit.²⁰ But raw drug price doesn’t capture the whole picture. Sugammadex has been associated with shorter operating room times and shorter stays in the recovery unit, which can save money on the facility and staffing side.²¹

Whether sugammadex actually saves money overall depends on who you’re looking at. A large analysis using U.S. national data found that sugammadex was associated with about $232 lower total hospital costs on average. But that average masked a split: in lower-risk patients, sugammadex was linked to about $1,042 in savings, while in higher-risk patients (those with more severe illness or who were already hospitalized before surgery), it was associated with about $620 in additional costs.²² The economics, like the pharmacology, aren’t one-size-fits-all.

Emergency Rescue Use

One scenario that has generated particular interest is the “can’t intubate, can’t ventilate” crisis, the nightmare situation where the anesthesiologist can’t get a breathing tube in and can’t effectively ventilate the patient by other means. If the patient was given rocuronium to facilitate intubation, the idea is to reverse the paralysis with sugammadex so the patient can resume breathing on their own while the team regroups. A systematic review of published case reports found that in six out of eight cases, adequate spontaneous breathing returned after sugammadex was given. In the remaining two, breathing returned in an obstructed pattern and a surgical airway was ultimately needed.²³ The doses used varied widely, and the evidence base is thin enough that sugammadex cannot be considered a reliable rescue strategy on its own. But in a life-threatening airway emergency, it’s one more tool in the kit.

1
Journal of Molecular Liquids. Theoretical studies on the mechanism of sugammadex for the reversal of aminosteroid-induced neuromuscular blockade
2
PubMed. Sugammadex hypersensitivity: a multicentre retrospective analysis of a large Australian cohort
3
Anesthesiology. Sugammadex Anaphylaxis: Mechanisms, Diagnosis, and Incidence
4
PubMed Central. Sugammadex induced bradycardia and hypotension: a case report and literature review
5
PubMed Central. Severe Hypotension, Bradycardia and Asystole after Sugammadex Administration in an Elderly Patient
6
PubMed Central. Sugammadex-induced bronchospasm: a case report
7
PubMed Central. Risk of bronchospasm and coronary arteriospasm with sugammadex use: a post marketing analysis
8
Anesthesia and Pain Medicine. What we need to know and do on sugammadex usage in pregnant and lactating women and those on hormonal contraceptives
9
PubMed Central. Effects of sugammadex on coagulation: a systematic review and meta-analysis
10
BJA: British Journal of Anaesthesia. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study
11
British Journal of Anaesthesia. Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg−1 for reversal of deep neuromuscular blockade in patients with severe renal impairment
12
PubMed. Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials
13
European Journal of Cardiovascular Medicine. Sugammadex Versus Neostigmine for Reversal of Rocuronium Block: Recovery Profile and Adverse Events- A Comparative Study
14
PubMed. Safety, tolerability and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects
15
PubMed. Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modelling approach
16
PubMed Central. Preparing for the unexpected: special considerations and complications after sugammadex administration
17
PubMed Central. Efficacy and safety of sugammadex for neuromuscular blockade reversal in pediatric patients: an updated meta-analysis of randomized controlled trials with trial sequential analysis
18
PubMed Central. Sugammadex: Safety Profile and Adverse Effects in Infants Less Than Two Years of Age With Congenital Heart Disease
19
PubMed Central. Sugammadex: A savior for an elderly cardiac patient! A case report
20
PubMed Central. Cost-Effectiveness of Sugammadex Versus Neostigmine to Reverse Neuromuscular Blockade in a University Hospital in Taiwan
21
PubMed Central. Sugammadex versus neostigmine for routine reversal of neuromuscular blockade and the effect on perioperative efficiency
22
PubMed. Comparison of the effects of sugammadex versus neostigmine for reversal of neuromuscular block on hospital costs of care
23
PubMed. Use of Sugammadex in “Cannot Intubate, Cannot Ventilate” Scenarios: A Systematic Review of Case Reports